Vasodilator therapy for pulmonary hypertension in children: a national study of patient characteristics and current treatment strategies

1. Hansmann, G, Koestenberger, M, Alastalo, T-P, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant 2019; 38: 879–901.
Google Scholar | Crossref | Medline2. Cerro, MJ, Abman, S, Diaz, G, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ 2011; 1: 286–298.
Google Scholar | SAGE Journals3. Simonneau, G, Gatzoulis, MA, Adatia, I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34–D41.
Google Scholar | Crossref | Medline | ISI4. Rosenzweig, EB, Abman, SH, Adatia, I, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J 2019; 53: 1801916.
Google Scholar | Crossref | Medline5. Simonneau, G, Montani, D, Celermajer, DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913.
Google Scholar | Crossref | Medline6. Marín, MJdC, Rotés, AS, Ogando, AR, et al. Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish Registry. Am J Respir Crit Care Med 2014; 190: 1421–1429.
Google Scholar | Crossref | Medline7. van Loon, RLE, Roofthooft, MTR, Hillege, HL, et al. Pediatric pulmonary hypertension in the Netherlands. Circulation 2011; 124: 1755–1764.
Google Scholar | Crossref | Medline | ISI8. Farber, HW, Miller, DP, Poms, AD, et al. Five-year outcomes of patients enrolled in the REVEAL registry. Chest 2015; 148: 1043–1054.
Google Scholar | Crossref | Medline | ISI9. Berger, RMF, Beghetti, M, Humpl, T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012; 379: 537–546.
Google Scholar | Crossref | Medline | ISI10. www.socialstyrelsen.se/en/statistics-and-data/registers/. (accessed 28 October 2021).
Google Scholar11. www.whocc.no/atc/structure_and_principles/. (accessed 28 October 2021).
Google Scholar12. https://www.who.int/standards/classifications/classification-of-diseases. (accessed 28 October 2021).
Google Scholar13. Galie, N, Humbert, M, Vachiery, JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67–119.
Google Scholar | Crossref | Medline | ISI14. Statistics Sweden, Population and Welfare Statistics 2016:1, Personal identity number.
Google Scholar | Crossref15. Castaldi, B, Bordin, G, Padalino, M, et al. Hemodynamic impact of pulmonary vasodilators on single ventricle physiology. Cardiovasc Ther 2018; 36: e12314.
Google Scholar | Crossref16. Jeremiasen, I, Tran-Lundmark, K, Idris, N, et al. Pulmonary vasodilator therapy in children with single ventricle physiology: effects on saturation and pulmonary arterial pressure. Pediatr Cardiol 2020; 41: 1651–1659.
Google Scholar | Crossref | Medline17. Bush, D, Galambos, C, Ivy, DD, et al. Clinical characteristics and risk factors for developing pulmonary hypertension in children with Down syndrome. J Pediatr 2018; 202: 212–219.
Google Scholar | Crossref | Medline18. Bush, D, Galambos, C, Dunbar, Ivy D . Pulmonary hypertension in children with Down syndrome. Pediatr Pulmonol 2020; 56: 621–629.
Google Scholar | Crossref | Medline19. Humpl, T, Reyes, JT, Holtby, H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111: 3274–3280.
Google Scholar | Crossref | Medline | ISI20. Barst, R. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372–382.
Google Scholar | Crossref | Medline | ISI21. Abrams, D, Schulze-Neick, I, Magee, AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4.
Google Scholar | Crossref | Medline22. Barst, RJ, Ivy, DD, Gaitan, G, et al. A Randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125: 324–334.
Google Scholar | Crossref | Medline | ISI23. Barst, RJ, Beghetti, M, Pulido, T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation 2014; 129: 1914–1923.
Google Scholar | Crossref | Medline | ISI24. Cohen, JL, Nees, SN, Valencia, GA, et al. Sildenafil use in children with pulmonary hypertension. J Pediatr 2019; 205: 29–34 e21.
Google Scholar | Crossref | Medline25. Berger, RMF, Gehin, M, Beghetti, M, et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. Br J Clin Pharmacol 2017; 83: 1734–1744.
Google Scholar | Crossref | Medline26. Berger, RMF, Haworth, SG, Bonnet, D, et al. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J Cardiol 2016; 202: 52–58.
Google Scholar | Crossref | Medline27. Zijlstra, WMH, Douwes, JM, Rosenzweig, EB, et al. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol 2014; 63: 2159–2169.
Google Scholar | Crossref | Medline | ISI28. Krishnan, U, Feinstein, JA, Adatia, I, et al. Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J Pediatr 2017; 188: 24–34, e21.
Google Scholar | Crossref | Medline29. Apitz, C, Hansmann, G, Schranz, D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016; 102 Suppl 2: ii23–29.
Google Scholar | Crossref | Medline30. Barst, RJ, McGoon, MD, Elliott, CG, et al. Survival in childhood pulmonary arterial hypertension. Circulation 2012; 125: 113–122.
Google Scholar | Crossref | Medline | ISI

留言 (0)

沒有登入
gif